Veltri R W, Raich P C, McClung J E, Shah S H, Sprinkle P M
Cancer. 1982 Oct 15;50(8):1513-7. doi: 10.1002/1097-0142(19821015)50:8<1513::aid-cncr2820500811>3.0.co;2-8.
A case report of a patient with lymphomatoid granulomatosis presenting initially as a reactivated Epstein-Barr virus infection is presented. Epstein-Barr virus is proposed in the possible role of establishing of an immunologically compromised state that may have set the stage for dissemination of this disease process. Of interest is the fact that successful chemotherapeutic management of the disease was accomplished using prednisone and cyclophosphamide. Furthermore, this clinical success was reflected in a decreasing Epstein-Barr virus early antigen-antibody titers accompanied by increasing antivirus capsid antigen titers; hence, it appears that laboratory markers of the response of lymphomatoid granulomatosis to treatment are available in the form of soluble immune complexes, antibodies to Epstein-Barr virus-coded antigens early antigens, Epstein-Barr nuclear antigens and/or virus capsid antigens as well as the active E rosette assay for T-cells. Finally, these data, although supporting the role of Epstein-Barr virus in the pathogenesis of lymphomatoid granulomatosis, suggest the need for further study in additional patients to verify the results.
本文报告了一例最初表现为复发性爱泼斯坦-巴尔病毒感染的淋巴瘤样肉芽肿病患者。爱泼斯坦-巴尔病毒被认为可能在建立免疫受损状态中起作用，这种状态可能为该疾病进程的传播奠定了基础。有趣的是，使用泼尼松和环磷酰胺成功地对该疾病进行了化疗管理。此外，这种临床成功反映在爱泼斯坦-巴尔病毒早期抗原抗体滴度下降，同时抗病毒衣壳抗原滴度升高；因此，似乎淋巴瘤样肉芽肿病对治疗反应的实验室标志物可以以可溶性免疫复合物、针对爱泼斯坦-巴尔病毒编码抗原早期抗原、爱泼斯坦-巴尔核抗原和/或病毒衣壳抗原的抗体以及T细胞活性E花环试验的形式获得。最后，这些数据虽然支持爱泼斯坦-巴尔病毒在淋巴瘤样肉芽肿病发病机制中的作用，但表明需要对更多患者进行进一步研究以验证结果。
